查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615417

学名药市场：按类型、给药途径、适应症、药物、分销分类 - 全球预测 2025-2030

Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Drug, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年学名药市场规模为2,991.6亿美元，预计2024年将达3,162.7亿美元，复合年增长率为5.91%，2030年将达4,474.5亿美元。

学名药市场的范围和定义包括基于专利保护期满的原厂药开发的、可以由多个製造商生产且不侵犯知识产权的药品。对学名药的需求在于其可负担性和可用性，透过提供昂贵的品牌药的成本效益替代品来帮助降低医疗成本并扩大患者的可及性。其应用涵盖广泛的治疗领域，从糖尿病、高血压等慢性疾病到急性感染疾病，在医院、诊所和零售药局都有大量存在。最终用途包括优先考虑具有成本效益的治疗方案的个别患者、医疗保健提供者和政府医疗保健系统。影响该市场的关键成长要素包括慢性病盛行率上升、新兴国家医疗保健支出增加以及有利于学名药快速核准的法规环境的发展。

主要市场统计
基准年[2023] 2991.6亿美元
预计年份 [2024] 3162.7亿美元
预测年份 [2030] 4474.5亿美元
复合年增长率（%） 5.91%

随着医疗基础设施不断扩大，新兴国家的开拓市场以及生物相似药领域存在着成长机会，特别是在生物製药预计即将专利到期的情况下。公司可以透过投资策略联盟、製造能力和有针对性的行销来利用这些机会。然而，激烈的市场竞争、严格的监管要求以及与药品品质和召回相关的问题等限制可能会阻碍成长。定价压力以及平衡盈利和负担能力的需求也带来了挑战。

创新和研发包括药物输送系统的进步、复杂学名药的开发以及製造流程的永续性。透过专注于利基治疗领域并利用人工智慧和巨量资料进行药物开发和优化来获得市场开拓。市场动态是动态的、竞争性的，需要不断适应监管变化和市场需求。为了利用这些动态，公司必须优先考虑强大的品管系统和投资专门的学名药，从而在拥挤的市场环境中脱颖而出。

市场动态：揭示快速发展的学名药市场的关键市场洞察

供需的动态交互作用正在改变学名药市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病盛行率上升以及对具有成本效益的药物的需求
    • 政府对学名药的支持
    • 透过线上药局增加学名药的供应
  • 市场限制因素
    • 病人和医生对品牌药物的偏好
  • 市场机会
    • 与学名药开发相关的持续研究和开发活动
    • 专利到期和战略长期联盟增加以生产学名药
  • 市场挑战
    • 对品质和製造差异的担忧

波特五力：驾驭学名药市场的策略工具

波特五力框架是了解学名药市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对学名药市场的影响

外部宏观环境因素对学名药市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解学名药市场竞争状况

对学名药市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵供应商在学名药市场绩效评估

FPNV定位矩阵是评估学名药市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製学名药市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，学名药市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的增加和对具有成本效益的药物的需求
      • 政府对学名药的优惠支持
      • 透过线上药局增加学名药的可得性
    • 抑制因素
      • 病人和医生对品牌药物的偏好
    • 机会
      • 与学名药开发相关的持续研发活动
      • 专利到期并增加製造学名药的战略长期伙伴关係
    • 任务
      • 对品质和製造差异的担忧
  • 市场区隔分析
    • 类型：扩大应用于复杂和慢性疾病的治疗
    • 分销：由于便利性、可近性和具竞争力的价格，网路药局越来越受青睐。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章学名药市场：按类型

  • 简单非专利
  • 特殊非专利

第七章学名药市场：依管理途径

  • 吸入式
  • 可注射的
  • 口服

第八章学名药市场（按适应症）

  • 癌症
  • 心血管疾病
  • 中枢神经系统疾病
  • 糖尿病
  • 消化系统疾病
  • 荷尔蒙与相关疾病
  • 感染疾病
  • 呼吸系统疾病

第九章学名药市场（按药品）

  • Acetazolamide
  • 阿维A
  • Atorvastatin
  • 阿奇霉素
  • Carbamazepine
  • 西酞普兰
  • Clopidogrel
  • 多奈哌齐
  • escitalopram
  • Esomeprazole
  • Fluticasone
  • Gabapentin
  • 氢氯噻嗪
  • 左旋甲状腺素
  • Lisinopril
  • 氯沙坦
  • 奥美拉唑
  • Posaconazole
  • rosuvastatin
  • 舍曲林
  • Simvastatin
  • Tamsulosin
  • Warfarin

第十章学名药市场经销商

  • 医院药房
  • 网路药房
  • 零售药房

第十一章美洲学名药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区学名药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲学名药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • BDR Pharma 推出治疗真菌感染疾病的学名药，价格仅为三分之一
    • Amneal 推出已获批准的非专利Xyrem（奥昔巴特钠），并获得 FDA核准其五种复合非专利
    • Mediplus Health Service 推出自有品牌学名药
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals Inc
  • Aspen Holdings
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Cipla Ltd
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc.
  • Fresenius SE & Co. KGaA.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mylan NV by Viatris Inc.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis Group
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Lifesciences Ltd
Product Code: MRR-F6513A06BE93

The Generic Drugs Market was valued at USD 299.16 billion in 2023, expected to reach USD 316.27 billion in 2024, and is projected to grow at a CAGR of 5.91%, to USD 447.45 billion by 2030.

The scope and definition of the generic drugs market involve pharmaceuticals developed based on brand-name drugs whose patent protection has expired, allowing production by multiple manufacturers without intellectual property infringement. The necessity of generic drugs lies in their affordability and accessibility, offering cost-effective alternatives to expensive brand-name medications, thereby instrumental in reducing healthcare costs and expanding patient access. Their application spans a vast array of therapeutic areas, from chronic conditions like diabetes and hypertension to acute infections, contributing to their substantial presence in hospitals, clinics, and retail pharmacies. The end-use scope includes individual patients, healthcare providers, and governmental healthcare systems prioritizing cost-effective treatment options. Key growth factors influencing this market include the rising prevalence of chronic diseases, increased healthcare expenditure in emerging economies, and a supportive regulatory environment that encourages the expedited approval of generics.

KEY MARKET STATISTICS
Base Year [2023] USD 299.16 billion
Estimated Year [2024] USD 316.27 billion
Forecast Year [2030] USD 447.45 billion
CAGR (%) 5.91%

Opportunities for growth are present in untapped markets within developing countries where healthcare infrastructure is expanding, and in the biosimilar segment, particularly with the anticipated wave of biologic patent expirations. Companies can leverage these opportunities by investing in strategic collaborations, manufacturing capabilities, and targeted marketing. However, limitations such as intense market competition, stringent regulatory requirements, and issues related to drug quality and recalls can impede growth. Challenges also stem from pricing pressures and the need for maintaining a balance between profitability and affordability.

Innovation and research areas include advancements in drug delivery systems, development of complex generics, and sustainability in manufacturing processes. Market growth can be fueled by focusing on niche therapeutic areas and leveraging AI and big data for drug development and optimization. The nature of the generic drugs market is dynamic and competitive, with a constant need for adaptation to regulatory changes and market demands. To capitalize on these dynamics, organizations should prioritize robust quality management systems and invest in specialty generics to differentiate themselves in the crowded market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Drugs Market

The Generic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases and the need for cost-effective medications
    • Favorable government support for generic drugs
    • Growing availability of generic drugs through online pharmacies
  • Market Restraints
    • Preference for branded drugs by patients and physicians
  • Market Opportunities
    • Ongoing R&D activities associated with the development of generic drugs
    • Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
  • Market Challenges
    • Concerns associated with quality and manufacturing variability

Porter's Five Forces: A Strategic Tool for Navigating the Generic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Drugs Market

A detailed market share analysis in the Generic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Drugs Market

A strategic analysis of the Generic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Amneal Pharmaceuticals Inc, Aspen Holdings, Aurobindo Pharma Limited, Baxter International Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin Limited, Mylan N.V. by Viatris Inc., Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi S.A., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Zydus Lifesciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Simple Generic and Specialty Generic.
  • Based on Route of Administration, market is studied across Inhalable, Injectable, and Oral.
  • Based on Indication, market is studied across Cancer, Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Gastrointestinal Diseases, Hormones & Related Diseases, Infectious Diseases, and Respiratory Diseases.
  • Based on Drug, market is studied across Acetazolamide, Acitretin, Atorvastatin, Azithromycin, Carbamazepine, Citalopram, Clopidogrel, Donepezil, Escitalopram, Esomeprazole, Fluticasone, Gabapentin, Hydrochlorothiazide, Levothyroxine, Lisinopril, Losartan, Omeprazole, Posaconazole, Rosuvastatin, Sertraline, Simvastatin, Tamsulosin, and Warfarin.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and the need for cost-effective medications
      • 5.1.1.2. Favorable government support for generic drugs
      • 5.1.1.3. Growing availability of generic drugs through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with the development of generic drugs
      • 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding applications of for treating complex and chronic conditions
    • 5.2.2. Distribution: Emerging preference for online pharmacies for convenience, accessibility, and competitive pricing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Simple Generic
  • 6.3. Specialty Generic

7. Generic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalable
  • 7.3. Injectable
  • 7.4. Oral

8. Generic Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Central Nervous System Disorders
  • 8.5. Diabetes
  • 8.6. Gastrointestinal Diseases
  • 8.7. Hormones & Related Diseases
  • 8.8. Infectious Diseases
  • 8.9. Respiratory Diseases

9. Generic Drugs Market, by Drug

  • 9.1. Introduction
  • 9.2. Acetazolamide
  • 9.3. Acitretin
  • 9.4. Atorvastatin
  • 9.5. Azithromycin
  • 9.6. Carbamazepine
  • 9.7. Citalopram
  • 9.8. Clopidogrel
  • 9.9. Donepezil
  • 9.10. Escitalopram
  • 9.11. Esomeprazole
  • 9.12. Fluticasone
  • 9.13. Gabapentin
  • 9.14. Hydrochlorothiazide
  • 9.15. Levothyroxine
  • 9.16. Lisinopril
  • 9.17. Losartan
  • 9.18. Omeprazole
  • 9.19. Posaconazole
  • 9.20. Rosuvastatin
  • 9.21. Sertraline
  • 9.22. Simvastatin
  • 9.23. Tamsulosin
  • 9.24. Warfarin

10. Generic Drugs Market, by Distribution

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. BDR Pharma launches generic drug for fungal infections at 1/3rd the cost
    • 14.3.2. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.3. Mediplus Health Services launches own brand of generic medicines
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Ltd.
  • 3. Amneal Pharmaceuticals Inc
  • 4. Aspen Holdings
  • 5. Aurobindo Pharma Limited
  • 6. Baxter International Inc.
  • 7. Cipla Ltd
  • 8. Dr. Reddy's Laboratories Ltd.
  • 9. Eli Lilly and Company
  • 10. Endo International plc.
  • 11. Fresenius SE & Co. KGaA.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. Hikma Pharmaceuticals PLC.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Lupin Limited
  • 18. Mylan N.V. by Viatris Inc.
  • 19. Pfizer Inc.
  • 20. Sandoz International GmbH by Novartis Group
  • 21. Sanofi S.A.
  • 22. STADA Arzneimittel AG
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Teva Pharmaceuticals Industries Ltd.
  • 25. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY ACITRETIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY LEVOTHYROXINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC DRUGS MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GENERIC DRUGS MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL GENERIC DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL GENERIC DRUGS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 180. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. NIGERIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 200. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NORWAY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 204. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 205. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. POLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 209. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 210. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. QATAR GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 214. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 215. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. RUSSIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 219. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 220. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 224. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 230. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SPAIN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 234. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 235. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. SWEDEN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 239. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 240. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 244. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 245. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. TURKEY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 249. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 250. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 254. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 261. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023